



an Open Access Journal by MDPI

Combining Immunotherapy and Targeted Therapies in Cancer Treatment

Guest Editors:

**Dr. Aleksandra Grela-
Wojewoda**

Department of Clinical Oncology,
The Maria Skłodowska-Curie
National Research Institute of
Oncology, Kraków Branch, 31-
115 Kraków, Poland

Prof. Dr. Wojciech Wysocki

Department of Surgery, Faculty
of Medicine and Health Sciences,
Andrzej Frycz Modrzewski Krakow
University, 30-705 Kraków,
Poland

Dr. Marek Ziobro

Department of Clinical Oncology,
Maria Skłodowska-Curie National
Research Institute of Oncology,
Kraków Branch, 31-115 Kraków,
Poland

Deadline for manuscript
submissions:

closed (25 June 2024)

Message from the Guest Editors

Dear Colleagues,

Cancer is an increasing epidemiological issue worldwide. Molecularly targeted therapies directed at various molecular targets, along with immunotherapy, have fundamentally transformed the therapeutic outlook for patients undergoing radical or palliative treatment for cancer. Targeted therapies are widely utilized in the fields of hematology and oncology. Novel approaches to combination therapy in the context of overcoming resistance represent a compelling subject that merits investigation. This Special Issue warmly welcomes fundamental and translational research, original articles, and concise communications that focus on innovative anti-cancer strategies. Special attention will be given to manuscripts that describe molecular mechanisms of drug resistance, predictive biomarkers, as well as original contributions that present real-world evidence and introduce novel action protocols.



mdpi.com/si/174956

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com